Which Came First? Alogliptin Avoids Possible Exclusivity Dispute
This article was originally published in RPM Report
Executive Summary
An unusual footnote in FDA’s approval letter for Takeda’s long-delayed diabetes medicine means that the company won’t have to worry about losing five-year exclusivity on the molecule.
You may also be interested in...
NCE Market Exclusivity: Eisai Targets DEA Scheduling Delays, Pozen Pushes Bill For Combo Products
Eisai citizen petition requests Belviq and Fycompa approval dates coincide with final DEA scheduling; Pozen advocates exclusivity for new combinations of previously approved molecules.
Much “Ado” About Biosimilars
The approval of Kadcyla gives Roche/Genentech yet another new breakthrough cancer therapy in the US. It also offers some clues about the future of biosimilars at FDA.
Takeda’s Hat Trick Marks The First New Molecular Entity Of 2013
Takeda’s type 2 diabetes drug alogliptin – on its third pass through FDA – was cleared Jan. 25 as a single agent as Nesina, in combination with metformin as Kazano and in combination with pioglitazone as Oseni.